David G Wood, MD | |
516 Main St Ste 282, Salmon, ID 83467-4219 | |
(505) 466-3175 | |
Not Available |
Full Name | David G Wood |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Location | 516 Main St Ste 282, Salmon, Idaho |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1932205234 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | 016023 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
David G Wood, MD 516 Main St Ste 282, Salmon, ID 83467-4219 Ph: (505) 466-3175 | David G Wood, MD 516 Main St Ste 282, Salmon, ID 83467-4219 Ph: (505) 466-3175 |
News Archive
Johns Hopkins surgeons say skipping one commonly taken step during a routine procedure to insert a wire mesh stent into a partially blocked carotid artery appears to prevent patients from developing dangerously low blood pressure, an extremely slow heart rate or even a stroke or heart attack.
IRX Therapeutics, a developer of novel immunomodulators to treat cancer and viral diseases, today announced that it has established a strategic collaboration with Japan's National Cancer Research Center (NCRC) to evaluate next-generation peptide-based cancer vaccines. Clinical research will be conducted at NCRC. IRX Therapeutics will provide its proprietary IRX-2 immunomodulatory regimen, clinical trial design and technical support. This is the first collaboration of its kind between the NCRC and a U.S.-based biotechnology firm.
When a baby is born small, it's often attributed to genetic factors or maternal risk factors like poor nutrition or smoking.
African American youth who report experiencing frequent discrimination during adolescence are at risk for developing heart disease, high blood pressure, diabetes, and stroke in later years, according to a new study.
› Verified 3 days ago